Oncolytic viruses: Revolutionising the fight against tumours

Zeda Zhao; Yinan Shen; Tingbo Liang

doi:10.1002/ctm2.70503

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (10) : e70503 DOI: 10.1002/ctm2.70503

INVITED LETTER

Oncolytic viruses: Revolutionising the fight against tumours

Author information +

History +

PDF

Cite this article

Download citation ▾

Zeda Zhao, Yinan Shen, Tingbo Liang. Oncolytic viruses: Revolutionising the fight against tumours. Clinical and Translational Medicine, 2025, 15(10): e70503 DOI:10.1002/ctm2.70503

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Dock G. The influence of complicating diseases upon leukaemia. Am J Med Sci (1827–1924). 1904; 127: 563.

[2]	Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DMJS. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252: 854-856.

[3]	Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013; 19: 329-336.

[4]	Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010; 17: 718-730.

[5]	Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006; 14: 361-370.

[6]	Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90: 3539-3543.

[7]	Tamadaho RSE, Hoerauf A, Layland LE. Immunomodulatory effects of myeloid-derived suppressor cells in diseases: role in cancer and infections. Immunobiology. 2018; 223: 432-442.

[8]	Shen Y, Bai X, Zhang Q, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025; 641: 503-511.

[9]	Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017; 170: 1109-1119. e1110.

[10]	Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022; 28: 1630-1639.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.